Objective:To investigate the clinical features, diagnosis and treatment of somatoform disorders (according to ICD-10 criteria) in outpatients of internal medicine department.Methods:96 patients with somatoform disorde...Objective:To investigate the clinical features, diagnosis and treatment of somatoform disorders (according to ICD-10 criteria) in outpatients of internal medicine department.Methods:96 patients with somatoform disorders being misdiagnosed and followed-up at the internal medicine outpatient department were rated using Self-Rating Depression Scale (SDS) and HAMD, and they were re-diagnosed according to ICD-10 criteria. Paroxetine were used to treat these patients with somatoform disorders.Results: All of the 96 Patients met the ICD-10 somatoform disorders criteria. Somatization disorder was the most frequent subtype diagnoses, and pain was the most frequent complaint among the somatoform symptoms. The patients’ symptoms significantly improved after 8 weeks anti-depression treatment.Conclusion:Timely recognition and diagnosis of the somatoform disorders in internal medicine department may decrease the probability of inappropriate medical treatment. Antidepressants have efficiency for improving somatic and mental symptoms.展开更多
Objective: To compare the effects between haloperidol and rieperidone on quality of life in patients with schizophrenia. Methods: The patients with schizophrenia treated respectively by haloperidol and risperidone wer...Objective: To compare the effects between haloperidol and rieperidone on quality of life in patients with schizophrenia. Methods: The patients with schizophrenia treated respectively by haloperidol and risperidone were compared by double blind method. The General Quality of Life Inventory (GQOLI) was used to evaluate the life quality, while the Positive and Negative Symptoms Scale (PANSS) and the Treatment Emergent Symptom Scale (TESS) were used to assess the efficacy and side effects. Results: The risperidone group showed better effects than the haloperidol group in the domains of physical function ,mental health and social function The difference was significant (P<0.01). Conclusion: The quality of life of Schizophrenic patients treated by haloperidol were poorer than that of risperidone.展开更多
文摘Objective:To investigate the clinical features, diagnosis and treatment of somatoform disorders (according to ICD-10 criteria) in outpatients of internal medicine department.Methods:96 patients with somatoform disorders being misdiagnosed and followed-up at the internal medicine outpatient department were rated using Self-Rating Depression Scale (SDS) and HAMD, and they were re-diagnosed according to ICD-10 criteria. Paroxetine were used to treat these patients with somatoform disorders.Results: All of the 96 Patients met the ICD-10 somatoform disorders criteria. Somatization disorder was the most frequent subtype diagnoses, and pain was the most frequent complaint among the somatoform symptoms. The patients’ symptoms significantly improved after 8 weeks anti-depression treatment.Conclusion:Timely recognition and diagnosis of the somatoform disorders in internal medicine department may decrease the probability of inappropriate medical treatment. Antidepressants have efficiency for improving somatic and mental symptoms.
文摘Objective: To compare the effects between haloperidol and rieperidone on quality of life in patients with schizophrenia. Methods: The patients with schizophrenia treated respectively by haloperidol and risperidone were compared by double blind method. The General Quality of Life Inventory (GQOLI) was used to evaluate the life quality, while the Positive and Negative Symptoms Scale (PANSS) and the Treatment Emergent Symptom Scale (TESS) were used to assess the efficacy and side effects. Results: The risperidone group showed better effects than the haloperidol group in the domains of physical function ,mental health and social function The difference was significant (P<0.01). Conclusion: The quality of life of Schizophrenic patients treated by haloperidol were poorer than that of risperidone.